Pomalidomide Plus Low-Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients: Results of the Real-World “POWERFUL” Study

The “POWERFUL” multicenter, retrospective, and prospective study investigated the effectiveness of pomalidomide plus low-dose dexamethasone (POM/LoDex) therapy in relapsed/refractory multiple myeloma in routine care in Greece. Ninety-nine eligible adult patients treated with POM/LoDex according to t...

Descripción completa

Detalles Bibliográficos
Autores principales: Terpos, Evangelos, Repousis, Panagiotis, Lalayanni, Chrysavgi, Hatjiharissi, Evdoxia, Assimakopoulou, Theodora, Vassilopoulos, Georgios, Pouli, Anastasia, Spanoudakis, Emmanouil, Michalis, Eurydiki, Pangalis, Gerassimos, Ntanasis-Stathopoulos, Ioannis, Poziopoulos, Christos, Kyrtsonis, Marie-Christine, Pappa, Vasiliki, Symeonidis, Argiris, Georgopoulos, Christos, Zikos, Panagiotis M., Gavriatopoulou, Maria, Papadaki, Helen A., Dadakaridou, Magdalini, Karvounis-Marolachakis, Kiki, Katodritou, Eirini
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8038613/
https://www.ncbi.nlm.nih.gov/pubmed/33916376
http://dx.doi.org/10.3390/jcm10071509

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8038613/
https://www.ncbi.nlm.nih.gov/pubmed/33916376
http://dx.doi.org/10.3390/jcm10071509

Ejemplares similares